Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

nticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop PS433540, a product candidate from its DARA program, Pharmacopeia's Phase 1 and Phase 2 clinical studies with respect to PS433540, including timing and expected outcomes of such studies, Pharmacopeia's estimates of the market opportunities for its product candidates, including PS433540, Pharmacopeia's ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia's ability to raise additional capital, Pharmacopeia's expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia's anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia's expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia's ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.

Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commissi
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Luminex Corporation (NASDAQ: LMNX ) today announced financial ...  Financial and operating highlights for the quarter include the ... by 6 percent to $58.9 million, over the second ... assay revenue by 22 percent to $24.2 million over ... Increased Q2 2015 royalty revenue by 17 percent to ...
(Date:8/3/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ), the ... quarter ended June 30, 2015. All comparisons, unless otherwise noted, ... Second Quarter 2015 Highlights include: , Revenue ... , Total prescriptions dispensed of 234,000, an increase of ... , Adjusted EBITDA of $22.7 million, an increase of 287% ...
(Date:8/3/2015)... BUFFALO, N.Y. , Aug. 3, 2015 /PRNewswire/ ... the Wilmot Cancer Institute to the OmniSeq SM ... from Roswell Park Cancer Institute (RPCI) and announced ... products that support a physician-driven, collaborative approach to ... patient outcomes.  Wilmot Cancer Institute is a rapidly ...
Breaking Medicine Technology:Luminex Corporation Reports Record 2nd Quarter 2015 Results 2Luminex Corporation Reports Record 2nd Quarter 2015 Results 3Luminex Corporation Reports Record 2nd Quarter 2015 Results 4Luminex Corporation Reports Record 2nd Quarter 2015 Results 5Luminex Corporation Reports Record 2nd Quarter 2015 Results 6Luminex Corporation Reports Record 2nd Quarter 2015 Results 7Luminex Corporation Reports Record 2nd Quarter 2015 Results 8Luminex Corporation Reports Record 2nd Quarter 2015 Results 9Luminex Corporation Reports Record 2nd Quarter 2015 Results 10Luminex Corporation Reports Record 2nd Quarter 2015 Results 11Luminex Corporation Reports Record 2nd Quarter 2015 Results 12Luminex Corporation Reports Record 2nd Quarter 2015 Results 13Luminex Corporation Reports Record 2nd Quarter 2015 Results 14Luminex Corporation Reports Record 2nd Quarter 2015 Results 15Luminex Corporation Reports Record 2nd Quarter 2015 Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... , MORRISVILLE, N.C., Dec. ... the investigation of devices for minimally-invasive treatment for heart ... trial designed to evaluate the safety and efficacy of ... for the treatment of symptomatic paroxysmal atrial fibrillation (AF). ...
... , ALBUQUERQUE, N.M., Dec. 1 Exagen ... and markets proprietary genomic tests, today announced the appointment ... of directors and chief executive officer. , Prior to ... Partners and founder of a number of successful biomedical ...
Cached Medicine Technology:nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 2Scott Glenn Joins Exagen Diagnostics as Chairman and CEO 2
(Date:8/4/2015)... ... August 04, 2015 , ... It is National Psoriasis Awareness ... and its uncomfortable symptoms such as dry, itching, burning or soreness of skin that ... to medication before they find what’s right for them. Then, what is effective may ...
(Date:8/4/2015)... , ... August 04, 2015 , ... Centurion Service Group, ... over 1,000 pieces of used medical equipment. , The live auction will ... sold at their Fort Lauderdale warehouse located at 5025 North Hiatus Road Sunrise, FL ...
(Date:8/4/2015)... York, NY (PRWEB) , ... August 04, 2015 , ... ... all but universal, though the desire for invasive surgery to achieve this ideal is ... offer the results people crave without the high cost or lengthy recovery time, according ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of higher learning, announced today that its RN to BSN and Master ... been awarded full accreditation through June 2020 from the Commission on Collegiate ...
(Date:8/4/2015)... ... 04, 2015 , ... Nathan’s Famous was recently featured on NewsWatch ... large businesses making an impact in their industry. Andrew Tropeano, the host of NewsWatch ... hot dog maker now offers a 50% Reduced Fat All-Beef Frank variety and ...
Breaking Medicine News(10 mins):Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Medical Equipment Auction to Take Place in Fort Lauderdale 2Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... ... brand Intellicig has signed an exclusive deal which will see their products stocked in ... and Smiths News. , ... (PRWeb UK) February 2, 2010 -- Leading electronic cigarette brand Intellicig has signed ...
... , INDIANAPOLIS , Feb. 2 ... management is scheduled to present at the UBS 20th Annual Global ... 8:00 a.m. Eastern Standard Time .   , All interested parties ... visiting www.wellpoint.com and selecting the "Investor Info" ...
... cancer may increase a man,s risk of suicide or ... new study published online February 2 in the ... study the risks men diagnosed with prostate cancer in ... Channing Laboratory, Department of Medicine, Brigham and Women,s Hospital, ...
... ... to the Oakland University William Beaumont School of Medicine. , ... (Vocus) February 2, 2010 -- The Liaison Committee ... School of Medicine ., , , , ,The LCME is the national accrediting authority for ...
... study suggests, , TUESDAY, Feb. 2 (HealthDay News) -- ... sudden infant death syndrome (SIDS), new research finds. , Babies ... -- an important regulator of involuntary functions such as breathing ... other causes, the study found. This finding may eventually lead ...
... , , WASHINGTON , Feb. ... granted Wellness & Health Promotion (WHP) Accreditation to Medical Mutual of ... to complete the survey process for NCQA,s new program. , ... the United States to receive NCQA,s WHP Accreditation. , ...
Cached Medicine News:Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 2Health News:Intellicig Clinches Exclusive Deal with Retail Distribution-Giant to Distribute Their Industry Leading Electronic Cigarettes 3Health News:WellPoint Announces Appearance at Upcoming Conference 2Health News:WellPoint Announces Appearance at Upcoming Conference 3Health News:Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis 2Health News:Oakland University William Beaumont School of Medicine Reaches Development Milestone 2Health News:Serotonin May Be Key to Sudden Infant Deaths 2Health News:Serotonin May Be Key to Sudden Infant Deaths 3Health News:Medical Mutual is the First Ohio Health Plan to Receive NCQA Wellness & Health Accreditation 2
The Tri-Flex II system is a second generation healthcare patient support system that has the benefits of the original Tri-Flex system and multiple, updated support functions for increased comfort and...
... designed to make your bariatric patients feel comfortable ... them. , ,When caring for this population, ... in bed, turning, sitting, standing can be ... Care ES bed offers features to make these ...
... dignity. A single solution., ,Hill-Rom engineers ... added safety where its needed. Its long ... protect the caregiver and patient from injury, ... just like other TotalCare® beds, but its ...
... We offer a wide selection of solutions ... therapy use. The sterile water for inhalation ... in plastic pour bottles in 500 and ... prefilled nebulizer kits or can be used ...
Medicine Products: